# Advantages and Limitations of Animal Schizophrenia Models

**Authors:** Magdalena Białoń, Agnieszka Wąsik

PMC · DOI: 10.3390/ijms23115968 · International Journal of Molecular Sciences · 2022-05-25

## TL;DR

This paper discusses the use of animal models to study schizophrenia, highlighting their benefits and limitations in understanding the disease and developing new treatments.

## Contribution

The paper provides an overview of different types of schizophrenia animal models and their limitations in reflecting human disease.

## Key findings

- Animal models of schizophrenia include pharmacological, genetic, and neurodevelopmental approaches.
- These models induce brain changes in rodents that resemble human schizophrenia symptoms.
- Despite their usefulness, animal models have limitations and do not fully replicate human mental illness.

## Abstract

Mental illness modeling is still a major challenge for scientists. Animal models of schizophrenia are essential to gain a better understanding of the disease etiopathology and mechanism of action of currently used antipsychotic drugs and help in the search for new and more effective therapies. We can distinguish among pharmacological, genetic, and neurodevelopmental models offering various neuroanatomical disorders and a different spectrum of symptoms of schizophrenia. Modeling schizophrenia is based on inducing damage or changes in the activity of relevant regions in the rodent brain (mainly the prefrontal cortex and hippocampus). Such artificially induced dysfunctions approximately correspond to the lesions found in patients with schizophrenia. However, notably, animal models of mental illness have numerous limitations and never fully reflect the disease state observed in humans.

## Linked entities

- **Diseases:** schizophrenia (MONDO:0005090)

## Full-text entities

- **Genes:** Grin1 (glutamate ionotropic receptor NMDA type subunit 1) [NCBI Gene 24408] {aka GluN1, NMDAR1, NR1}, Il2 (interleukin 2) [NCBI Gene 116562], Il4 (interleukin 4) [NCBI Gene 287287] {aka Il4e12}, Erbb4 (erb-b2 receptor tyrosine kinase 4) [NCBI Gene 13869] {aka Her4, c-erbB-4}, Th (tyrosine hydroxylase) [NCBI Gene 25085] {aka The}, Il4 (interleukin 4) [NCBI Gene 16189] {aka BSF-1, Il-4}, Grin1 (glutamate receptor, ionotropic, NMDA1 (zeta 1)) [NCBI Gene 14810] {aka GluN1, GluRdelta1, GluRzeta1, M100174, NMD-R1, NMDAR1}, Tgfb1 (transforming growth factor, beta 1) [NCBI Gene 59086] {aka Tgfb}, Cnbd2 (cyclic nucleotide binding domain containing 2) [NCBI Gene 70873] {aka 4921517L17Rik, 5430421B09Rik, Cris}, Ache (acetylcholinesterase) [NCBI Gene 83817], Il10 (interleukin 10) [NCBI Gene 16153] {aka CSIF, If2a, Il-10}, Tgfb1 (transforming growth factor, beta 1) [NCBI Gene 21803] {aka TGF-beta1, TGFbeta1, Tgfb, Tgfb-1}, Htr2a (5-hydroxytryptamine receptor 2A) [NCBI Gene 29595] {aka 5-HT2A, 5Ht-2}, Il1b (interleukin 1 beta) [NCBI Gene 24494] {aka IL-1F2}, Th (tyrosine hydroxylase) [NCBI Gene 21823], Mpo (myeloperoxidase) [NCBI Gene 303413], Cat (catalase) [NCBI Gene 12359] {aka 2210418N07, Cas-1, Cas1, Cs-1}, Syt1 (synaptotagmin 1) [NCBI Gene 25716] {aka P65}, Dlg4 (discs large MAGUK scaffold protein 4) [NCBI Gene 29495] {aka Dlgh4, PSD95, Sap90}, Dlg4 (discs large MAGUK scaffold protein 4) [NCBI Gene 13385] {aka Dlgh4, PSD-95, PSD95, SAP90, SAP90A}, Drd2 (dopamine receptor D2) [NCBI Gene 13489] {aka D2R, Drd-2}, Ptgs2 (prostaglandin-endoperoxide synthase 2) [NCBI Gene 19225] {aka COX2, Cox-2, PES-2, PGHS-2, PHS II, PHS-2}, Cnr1 (cannabinoid receptor 1) [NCBI Gene 12801] {aka CB-R, CB1, CB1A, CB1B, CB1R}, Cat (catalase) [NCBI Gene 24248] {aka CS1, Cas1, Cat01, Catl, Cs-1}, Ntrk2 (neurotrophic tyrosine kinase, receptor, type 2) [NCBI Gene 18212] {aka GP145-TrkB/GP95-TrkB, Tkrb, trk-B, trkB}, Dtnbp1 (dystrobrevin binding protein 1) [NCBI Gene 94245] {aka 5430437B18Rik, Bloc1s8, dysbindin, sdy}, Ngf (nerve growth factor) [NCBI Gene 18049] {aka Ngfb, beta-NGF}, Npy (neuropeptide Y) [NCBI Gene 109648] {aka 0710005A05Rik}, Tlr3 (toll-like receptor 3) [NCBI Gene 142980], Glul (glutamate-ammonia ligase) [NCBI Gene 24957] {aka Glns}, Slc6a4 (solute carrier family 6 member 4) [NCBI Gene 25553] {aka SERT}, Nos2 (nitric oxide synthase 2) [NCBI Gene 24599] {aka Nos2a, iNos}, Nfkbia (NFKB inhibitor alpha) [NCBI Gene 25493] {aka RL/IF-1}, Tnf (tumor necrosis factor) [NCBI Gene 21926] {aka DIF, TNF-a, TNF-alpha, TNFSF2, TNFalpha, Tnfa}, Gria1 (glutamate receptor, ionotropic, AMPA1 (alpha 1)) [NCBI Gene 14799] {aka 2900051M01Rik, Glr-1, Glr1, GluA1, GluR-A, GluRA}, ERBB4 (erb-b2 receptor tyrosine kinase 4) [NCBI Gene 2066] {aka ALS19, HER4, p180erbB4}, Pparg (peroxisome proliferator activated receptor gamma) [NCBI Gene 19016] {aka Nr1c3, PPAR-gamma, PPAR-gamma2, PPARgamma, PPARgamma2}, Syp (synaptophysin) [NCBI Gene 24804] {aka Syp1}, Nfkbia (nuclear factor of kappa light polypeptide gene enhancer in B cells inhibitor, alpha) [NCBI Gene 18035] {aka Nfkbi}, Bdnf (brain derived neurotrophic factor) [NCBI Gene 12064], Rbfox3 (RNA binding protein, fox-1 homolog (C. elegans) 3) [NCBI Gene 52897] {aka Fox-3, Hrnbp3, NeuN, Neuna60}, Syp (synaptophysin) [NCBI Gene 20977] {aka A230093K24Rik, Syn, p38}, Mapk14 (mitogen activated protein kinase 14) [NCBI Gene 81649] {aka CRK1, CSBP, CSPB1, Csbp1, Csbp2, Exip}, Ephb1 (Eph receptor B1) [NCBI Gene 24338] {aka Ephb2, Erk, elk}, TH (tyrosine hydroxylase) [NCBI Gene 7054] {aka DYT14, DYT5b, TYH}, Disc1 (DISC1 scaffold protein) [NCBI Gene 307940], Camkk2 (calcium/calmodulin-dependent protein kinase kinase 2, beta) [NCBI Gene 207565] {aka 6330570N16Rik, mKIAA0787}, Gad2 (glutamate decarboxylase 2) [NCBI Gene 24380] {aka gad65}, Camk2b (calcium/calmodulin-dependent protein kinase II, beta) [NCBI Gene 12323] {aka CaMKII}, Nrg1 (neuregulin 1) [NCBI Gene 211323] {aka 6030402G23Rik, ARIA, D230005F13Rik, GGF, GGFII, HRG}, Slc6a4 (solute carrier family 6 (neurotransmitter transporter, serotonin), member 4) [NCBI Gene 15567] {aka 5-HTT, Htt, Sert}, Ache (acetylcholinesterase) [NCBI Gene 11423], Tnf (tumor necrosis factor) [NCBI Gene 24835] {aka RATTNF, TNF-alpha, Tnfa}, Il6 (interleukin 6) [NCBI Gene 24498] {aka ILg6, Ifnb2}, COX2 (COXII) [NCBI Gene 26198] {aka COII}, Ntrk2 (neurotrophic receptor tyrosine kinase 2) [NCBI Gene 25054] {aka RATTRKB1, TRKB1, Tkrb, trk-B, trkB}, Ntf3 (neurotrophin 3) [NCBI Gene 81737], Pvalb (parvalbumin) [NCBI Gene 19293] {aka PV, Parv, Pva}, Htr2c (5-hydroxytryptamine (serotonin) receptor 2C) [NCBI Gene 15560] {aka 5-HT-1C, 5-HT-2C, 5-HT1C, 5-HT2C, 5-HT2cR, 5-HTR2C}, Gpx1 (glutathione peroxidase 1) [NCBI Gene 24404] {aka GSHPx, GSHPx-1}
- **Diseases:** Dopaminergic Hyperfunction (MESH:D000308), Schizophrenia (MESH:D012559), MIA (MESH:D000079262), neuroanatomical disorders (MESH:D009358), inflammatory (MESH:D007249), 22q11.2 deletion (MESH:D004062), HTR (MESH:D006258), behavioral deficits (MESH:D019958), dystonia (MESH:D004421), type II diabetes (MESH:D003924), dendritic abnormalitiesimpaired (MESH:D007635), development (MESH:D002658), pain (MESH:D010146), autism (MESH:D001321), positive symptoms (MESH:D012816), influenza (MESH:D007251), addictive behavior (MESH:D000437), amphetamine addicts (MESH:D019969), genetic (MESH:D030342), HIP (OMIM:142700), cognitive symptoms (MESH:D019954), DA (MESH:C567730), miscarriage (MESH:D000022), impairments in memory and learning (MESH:D007859), mental illness (MESH:D001523), Ventral Hippocampal Lesion (MESH:D006555), psychoses (MESH:D011618), impairment in working memory (MESH:D008569), cognitive schizophrenia-related (MESH:D000084202), FM;0.1 (MESH:C566917), neurological conditions (MESH:D019636), metabolic syndrome (MESH:D024821), neuropsychiatric diseases (MESH:D004194), PPI (MESH:C565433), hippocampal lesion (MESH:D001927), intellectual disability (MESH:D008607), carcinogenic (MESH:D011230), DBA (MESH:D029503), gliosis (MESH:D005911), hallucinations (MESH:D006212), mood and anxiety disorders (MESH:D001008), parkinsonism (MESH:D010302), neuronal dysfunction (MESH:D009461), hypersensitivity (MESH:D004342), hyperactivity (MESH:D006948), GLUergic hypofunction (MESH:D000309), cognitive (MESH:D003072), atrophy (MESH:D001284), DOI (MESH:D008232), depression (MESH:D003866), ADHD (MESH:D001289), Psychomotor hyperactivity (MESH:D011595), anxiety (MESH:D001007), stroke (MESH:D020521), impaired sensorimotor gating (MESH:D020233), neuronal death (MESH:D009410), deterioration of mental status (MESH:D060825), NVHL (MESH:D007232),  (MESH:D004195)
- **Species:** Danio rerio (leopard danio, species) [taxon 7955], Homo sapiens (human, species) [taxon 9606], Cercopithecidae (monkey, family) [taxon 9527], Rattus norvegicus (brown rat, species) [taxon 10116], Mus musculus (house mouse, species) [taxon 10090]
- **Mutations:** rs2270363
- **Cell lines:** FL — Homo sapiens (Human), Oligodendroglioma, Cancer cell line (CVCL_B1D4)

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC9181262/full.md

## Figures

1 figure with captions in the complete paper: https://tomesphere.com/paper/PMC9181262/full.md

## References

277 references — full list in the complete paper: https://tomesphere.com/paper/PMC9181262/full.md

---
Source: https://tomesphere.com/paper/PMC9181262